Topics
Glioblastoma | Treatment | Clinical trials | Tislelizumab (Anti PD1)
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Tislelizumab
Guo G, Zhang Z, Zhang J, Wang D, Xu S, Liu G, Gao Y, Mei J, Yan Z,
Zhao R, Wang M, Li T, Bu X.
Predicting
recurrent glioblastoma clinical outcome to immune checkpoint
inhibition and low-dose bevacizumab with tumor in situ fluid
circulating tumor DNA analysis.
Cancer
Immunol Immunother. 2024 Aug 6;73(10):193. doi:
10.1007/s00262-024-03774-7. PMID:
39105794. Interventional study. ˍ
Zhang J, Wang D, Liu G, Bu C, Lv G, Li M, Wei S, Zhang Z, Gao Y,
Yan Z, Ma C, Zhao R, Wang M, Shi Y, Bu X.
Dynamic
signature for the effectiveness of anti-PD-1 therapy combined with
vascular normalization therapy in recurrent glioblastoma: A
randomized phase 2 trial.
Cancer.
2026 Jan 15;132(2):e70253. doi:
10.1002/cncr.70253. PMID:
41533333.
Interventional study˰
ˍ